Nanoligent

Spain · Research

Nanoligent is a preclinical-stage biotechnology company based in Barcelona, Spain. Founded in 2017 as a spin-off from the Universitat Autònoma de Barcelona and the Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau, the company specializes in developing precision nanomedicines for cancer treatment. Nanoligent focuses on addressing metastasis by creating targeted drug therapies that selectively eliminate metastatic tumor cells expressing the CXCR4 receptor. The company's lead drug candidate targets metastatic colorectal cancer, chosen for its significant market potential and unmet medical need. Nanoligent's technology platform utilizes self-assembling protein nanoparticles for targeted drug delivery, aiming to enhance treatment efficacy while minimizing side effects. The company is currently in the preclinical stage, with promising data from animal models supporting its approach. Nanoligent is actively seeking funding to advance its lead candidate into clinical trials, with a goal of raising approximately €15-17 million. The leadership team includes experienced scientists and entrepreneurs dedicated to improving cancer therapies through innovative nanobiotechnology.